Prognostic Factors of Radiofrequency Ablation Plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis

Overview

Journal Int J Hepatol

Publisher Wiley

Specialty Gastroenterology

Date 2020 Dec 31

PMID 33381321

Citations 3

Authors

Ky Thai Doan

Long Nguyn Vit

Thinh Nguyen Tien

Binh Nguyen Canh

Hoai Ngo Thi

Ngoc Nguyen Thanh

Bieu Bui Quang

Quang Le Van

Hyun Woong Lee

Bang Mai Hong

Affiliations

Soon will be listed here.

Abstract

Introduction: Survival outcomes in patients with unresectable colorectal cancer (CRC) liver metastasis treated by radiofrequency ablation (RFA) combined with systemic chemotherapy and correlation with potential prognostic factors were investigated. . A retrospective cohort study was conducted on 61 CRC patients with unresectable liver metastasis who underwent liver tumor-directed percutaneous RFA combined with conventional systemic chemotherapy between October 2013 and September 2018. Survival analyses were conducted using the Kaplan-Meier method, and the log-rank test was used to characterize differences in the median survival time and the 1-year, 3-year, and 5-year overall survival rates of subgroups to identify prognostic factors.

Results: Median overall survival and progression-free survival of all patients were 32 and 14 months, respectively. The cumulative survival rates at 1-, 3-, and 5-years were 93.2%; 44.5%, and 38.2%, respectively. Univariate analysis revealed that pre-RFA serum CEA levels, Eastern Cooperative Oncology Group (ECOG) status, number of liver lesions, the size of the largest lesion, and the total lesion size were prognostic factors. However, multivariate analysis demonstrated that only the number of liver lesions and the size of the largest lesion were independent prognostic factors for survival.

Conclusion: RFA plus systemic chemotherapy provides an encouraging survival outcome for patients with unresectable CRC liver metastasis. Multivariate analysis demonstrated that the number and size of liver metastatic lesions are independent prognostic factors for survival.

Citing Articles

Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study.

Tran T, Nguyen H, Pham G, Thi Hoang C, Vu Q Ann Med Surg (Lond). 2023; 85(7):3334-3338.

PMID: 37427169 PMC: 10328601. DOI: 10.1097/MS9.0000000000000954.

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade.

Tomita K, Matsui Y, Uka M, Umakoshi N, Kawabata T, Munetomo K Jpn J Radiol. 2022; 40(10):1035-1045.

PMID: 36097234 PMC: 9529678. DOI: 10.1007/s11604-022-01335-5.

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward.

Lin Y, Paolucci I, Brock K, Odisio B Cancers (Basel). 2021; 13(16).

PMID: 34439081 PMC: 8394430. DOI: 10.3390/cancers13163926.

References

Gillams A, Lees W . Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum. 2000; 43(5):656-61. DOI: 10.1007/BF02235582. View

Sica G, Ji H, Ros P . CT and MR imaging of hepatic metastases. AJR Am J Roentgenol. 2000; 174(3):691-8. DOI: 10.2214/ajr.174.3.1740691. View

Engstrom P, Arnoletti J, Benson 3rd A, Chen Y, Choti M, Cooper H . NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009; 7(8):778-831. DOI: 10.6004/jnccn.2009.0056. View

Minami Y, Kudo M . Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver. 2013; 7(1):1-6. PMC: 3572308. DOI: 10.5009/gnl.2013.7.1.1. View

Konopke R, Roth J, Volk A, Pistorius S, Folprecht G, Zophel K . Colorectal liver metastases: an update on palliative treatment options. J Gastrointestin Liver Dis. 2012; 21(1):83-91. View

van Tilborg A, Meijerink M, Sietses C, van Waesberghe J, Mackintosh M, Meijer S . Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2010; 84(1002):556-65. PMC: 3473628. DOI: 10.1259/bjr/78268814. View

Ariff B, Lloyd C, Khan S, Shariff M, Thillainayagam A, Bansi D . Imaging of liver cancer. World J Gastroenterol. 2009; 15(11):1289-300. PMC: 2658841. DOI: 10.3748/wjg.15.1289. View

Hellman R, Krasnow A, Sudakoff G . Positron emission tomography for staging and assessment of tumor response of hepatic malignancies. Semin Intervent Radiol. 2011; 23(1):21-32. PMC: 3036305. DOI: 10.1055/s-2006-939838. View

Welch S, Spithoff K, Rumble R, Maroun J . Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2009; 21(6):1152-1162. DOI: 10.1093/annonc/mdp533. View

10.

Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M . Cancers in Vietnam-Burden and Control Efforts: A Narrative Scoping Review. Cancer Control. 2019; 26(1):1073274819863802. PMC: 6643189. DOI: 10.1177/1073274819863802. View

11.

Choti M, Sitzmann J, Tiburi M, Sumetchotimetha W, Rangsin R, Schulick R . Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235(6):759-66. PMC: 1422504. DOI: 10.1097/00000658-200206000-00002. View

12.

Ilic I, Jankovic S, Ilic M . Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One. 2016; 11(8):e0161912. PMC: 5006969. DOI: 10.1371/journal.pone.0161912. View

13.

Seifert J, Morris D . Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg. 1998; 228(2):201-8. PMC: 1191461. DOI: 10.1097/00000658-199808000-00009. View

14.

Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg S . Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012; 265(3):958-68. DOI: 10.1148/radiol.12111851. View

15.

Shady W, Petre E, Gonen M, Erinjeri J, Brown K, Covey A . Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology. 2015; 278(2):601-11. PMC: 4734163. DOI: 10.1148/radiol.2015142489. View

16.

Ou S, Xu R, Li K, Chen Y, Kong Y, Liu H . Radiofrequency ablation with systemic chemotherapy in the treatment of colorectal cancer liver metastasis: a 10-year single-center study. Cancer Manag Res. 2018; 10:5227-5237. PMC: 6217171. DOI: 10.2147/CMAR.S170160. View

17.

Chow F, Chok K . Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019; 11(2):150-172. PMC: 6393711. DOI: 10.4254/wjh.v11.i2.150. View

18.

Donadon M, Lleo A, Di Tommaso L, Soldani C, Franceschini B, Roncalli M . The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Front Oncol. 2018; 8:181. PMC: 5985314. DOI: 10.3389/fonc.2018.00181. View

19.

Govaert K, van Kessel C, Lolkema M, Ruers T, Borel Rinkes I . Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?. Curr Colorectal Cancer Rep. 2012; 8(2):130-137. PMC: 3343230. DOI: 10.1007/s11888-012-0122-9. View

20.

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A . Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244(2):254-9. PMC: 1602156. DOI: 10.1097/01.sla.0000217629.94941.cf. View